MarketPulse

central nervous system disorders

2 articles
The Motley FoolThe Motley Fool··Jonathan Ponciano

Biotech Darling Praxis Stock Soars 700% as Major Fund Doubles Down With $266M Bet

Deerfield Management boosts $PRAX stake to $266M as biotech stock surges 685% annually. Company eyes $20B+ pipeline revenue potential with two FDA applications pending.
PRAXFDA approvalbiotech
The Motley FoolThe Motley Fool··Jonathan Ponciano

Biotech Darling $PRAX Soars 685% as $80.5M Investment Bets on Dual FDA Filings

$PRAX surges 685% annually, securing $80.5M from Driehaus Capital. Two FDA applications pending for neurological therapies with potential $20B+ revenue.
TSMPRAXGHbiotechinstitutional investment